[vc_row][vc_column width=”1/2″][vc_column_text]
Selexys is a pharmaceutical company that developed a platform of Selectin Inhibition Technology consisting of therapies that target P-selectin glycoprotein ligand-1 (PSGL-1) and P-selectin to treat pain among those with sickle cell disease.[/vc_column_text][/vc_column][vc_column width=”1/4″][rd_vline color=”#1e73be”][/vc_column][vc_column width=”1/4″][vc_column_text]Year Founded: 2005
Year Partnered: 2009
Category: Biotech/Pharma
Fund: Accelerate, Oklahoma Seed Capital Fund
Acquired in 2017 by Novartis[/vc_column_text][/vc_column][/vc_row]